Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid Leukemia
- 13 March 2003
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (11) , 1048-1050
- https://doi.org/10.1056/nejme030009
Abstract
Chronic myeloid leukemia (CML) is a clonal stem-cell disorder in which the reciprocal translocation t(9;22) generates two novel fusion genes: BCR-ABL on the derivative 22q– (Philadelphia) chromosome, and ABL-BCR on chromosome 9q+. The ABL gene product is a protein tyrosine kinase, and the fusion protein BCR-ABL has constitutive kinase activity that deregulates signal transduction pathways, causing abnormal cell cycling, inhibition of apoptosis, and increased proliferation of cells. The natural course of the disease is usually characterized by three sequential phases (the chronic, accelerated, and blast-crisis phases), during which there is progressively more resistance to therapy.Interferon alfa therapy extends survival . . .Keywords
This publication has 10 references indexed in Scilit:
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugsLeukemia, 2002
- Expression of the β4 integrin subunit induces monocytic differentiation of 32D/v-Abl cellsBlood, 2002
- Implications of imatinib mesylate for hematopoietic stem cell transplantationSeminars in Hematology, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cellsBlood, 2000
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJNCI Journal of the National Cancer Institute, 1998
- Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized TrialsJNCI Journal of the National Cancer Institute, 1997